EirGen Pharma has sold its site to Horizon for $65 million and will transfer 40 employees to the company. The site is located in an Industrial Development Agency Ireland business park and will include a filling line and a freeze dryer that can be used for Horizon’s commercial medicines Tepezza, Uplizna and Krystexxa. It will also be used for drug development, the company said in a release.
OPKO Health, Inc., is a multinational biopharmaceutical and diagnostics company, announced that its subsidiary EirGen Pharma has entered into an agreement with Nicoya Macau Limited, an affiliate of Nicoya Therapeutics (Nicoya), for the development and commercialization in Greater China (mainland China, Hong Kong, Macau and Taiwan) of Rayaldee for the treatment of secondary hyperparathyroidism (SHPT) in patients with stage 3 or 4 chronic kidney disease (CKD). Nicoya is a leading biotechnology company incubated by 6 Dimensions Capital and its successor fund 120 Capital and other co-investors, and is focusing on the Greater China nephrology market.
MIAMI, June 17, 2021 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) announces that its subsidiary, EirGen Pharma, Ltd., has entered into a definitive agreement to sell one of its facilities in Waterford, Ireland to Horizon Therapeutics plc (Nasdaq: HZNP) for $65 million in cash less certain assumed and accrued liabilities relating to transferred employees. The facility houses EirGen’s sterile-fill-finish business. EirGen’s research and development employees who were located at the site will transition to a new facility.
Eirgen Pharma's Generic Toremifene Citrate Receives Approval in US